liraglutide subcutaneous prolonged-release (NEX-22) / Nanexa AB - LARVOL DELTA

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Nanexa AB | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Nanexa doses first patient in the 30 mg dose group in the Phase I study with NEX-22 (Nanexa Press Release) - "Nanexa AB announces today that the first patient has been dosed in the 30 mg dose group in the ongoing Phase I study with NEX-22, the company's one-month formulation of liraglutide...The ongoing Phase I study evaluates the pharmacokinetics, safety and tolerability of NEX-22, which uses Nanexa's patented PharmaShell technology to enable a controlled release of the drug over one month....Nanexa looks forward to sharing additional data and insights from the study as they become available."

Trial status • Type 2 Diabetes Mellitus

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Nanexa AB | Active, not recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects with T2D (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Nanexa AB | Trial completion date: Nov 2024 ➔ May 2025 | Trial primary completion date: Nov 2024 ➔ May 2025

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: Nanexa AB | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Nanexa AB | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D (clinicaltrials.gov) - P1 | N=9 | Not yet recruiting | Sponsor: Nanexa AB

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus